Gossamer Bio, Inc. Gains 31.9%
Wed, Jul 13, 2022 at 08:33 PM
Gossamer Bio, Inc. (GOSS:NASDAQ) soared at $9.51, representing a gain of 31.9%. On Wed, Jul 13, 2022, GOSS:NASDAQ hit a New 2-Week High of $9.51. The stock appeared on our News Catalysts scanner on Wed, Jul 13, 2022 at 07:46 AM in the 'PRIVATE PLACEMENT' category. From Wed, Jun 29, 2022, the stock recorded 44.44% Up Days and 60.00% Green Days
About Gossamer Bio, Inc. (GOSS:NASDAQ)
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It is focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its pipeline products include GB001 (DP2 Antagonist), GB002 (PDGF Receptor Kinase Inhibitor), GB004 (HIF-1a Stabilizer), and others.
Top 10 Gainers:
- XORTX Therapeutics Inc. (XRTX:NASDAQ), 47.15%
- ironSource Ltd. Class A (IS:NYSE), 47.09%
- TDH Holdings, Inc. (PETZ:NASDAQ), 42.23%
- NuCana plc (NCNA:NASDAQ), 41.4%
- Gossamer Bio, Inc. (GOSS:NASDAQ), 31.9%
- Rhythm Pharmaceuticals, Inc. (RYTM:NASDAQ), 31.48%
- Powerbridge Technologies Co., Ltd. (PBTS:NASDAQ), 24.34%
- The OLB Group, Inc. (OLB:NASDAQ), 23.86%
- Velo3D Inc. (VLD:NYSE), 22.22%
- CinCor Pharma Inc. (CINC:NASDAQ), 21.13%